Regular monitoring and management of cardiovascular adverse events are essential for patients receiving long-term tyrosine kinase inhibitor therapy.
Regular monitoring, early recognition, and appropriate interventions for CV AEs can help more patients derive the benefit of long-term TKI therapy.
Lenihan et al. (Thu,) studied this question.